ID   FIBA_HUMAN              Reviewed;         866 AA.
AC   P02671; A8K3E4; D3DP14; D3DP15; Q4QQH7; Q9BX62; Q9UCH2;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   07-APR-2021, entry version 251.
DE   RecName: Full=Fibrinogen alpha chain;
DE   Contains:
DE     RecName: Full=Fibrinopeptide A;
DE   Contains:
DE     RecName: Full=Fibrinogen alpha chain;
DE   Flags: Precursor;
GN   Name=FGA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS 1 AND
RP   2).
RX   PubMed=1457396; DOI=10.1021/bi00163a002;
RA   Fu Y., Weissbach L., Plant P.W., Oddoux C., Cao Y., Liang T.J., Roy S.N.,
RA   Redman C.M., Grieninger G.;
RT   "Carboxy-terminal-extended variant of the human fibrinogen alpha subunit: a
RT   novel exon conferring marked homology to beta and gamma subunits.";
RL   Biochemistry 31:11968-11972(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 1).
RA   Chung D.W., Grieninger G.;
RT   "Fibrinogen DNA and protein sequences.";
RL   (In) Ebert R.F. (eds.);
RL   Index of variant human fibrinogens, pp.13-24, CRC Press, Boca Raton (1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-6; ALA-331 AND ALA-456.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ALA-331.
RC   TISSUE=Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE OF 1-655 (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=2102623; DOI=10.1007/978-1-4615-3806-6_3;
RA   Chung D.W., Harris J.E., Davie E.W.;
RT   "Nucleotide sequences of the three genes coding for human fibrinogen.";
RL   Adv. Exp. Med. Biol. 281:39-48(1990).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=6575389; DOI=10.1073/pnas.80.13.3953;
RA   Kant J.A., Lord S.T., Crabtree G.R.;
RT   "Partial mRNA sequences for human A alpha, B beta, and gamma fibrinogen
RT   chains: evolutionary and functional implications.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:3953-3957(1983).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-629.
RX   PubMed=6688355; DOI=10.1021/bi00282a031;
RA   Rixon M.W., Chan W.-Y., Davie E.W., Chung D.W.;
RT   "Characterization of a complementary deoxyribonucleic acid coding for the
RT   alpha chain of human fibrinogen.";
RL   Biochemistry 22:3237-3244(1983).
RN   [10]
RP   PROTEIN SEQUENCE OF 20-629.
RA   Henschen A., Lottspeich F., Southan C., Topfer-Petersen E.;
RT   "Human fibrinogen: sequence, sulfur bridges, glycosylation and some
RT   structural variants.";
RL   (In) Peeters H. (eds.);
RL   Protides of the biological fluids, Proc. 28th colloquium, pp.51-56,
RL   Pergamon Press, Oxford (1980).
RN   [11]
RP   PROTEIN SEQUENCE OF 20-629, DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=518846; DOI=10.1021/bi00591a024;
RA   Watt K.W.K., Cottrell B.A., Strong D.D., Doolittle R.F.;
RT   "Amino acid sequence studies on the alpha chain of human fibrinogen.
RT   Overlapping sequences providing the complete sequence.";
RL   Biochemistry 18:5410-5416(1979).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 110-156.
RX   PubMed=6689067; DOI=10.1093/nar/11.21.7427;
RA   Imam A.M.A., Eaton M.A.W., Williamson R., Humphries S.;
RT   "Isolation and characterisation of cDNA clones for the A alpha- and gamma-
RT   chains of human fibrinogen.";
RL   Nucleic Acids Res. 11:7427-7434(1983).
RN   [13]
RP   NUCLEOTIDE SEQUENCE OF 605-644 (ISOFORM 2).
RX   PubMed=6575700; DOI=10.1111/j.1749-6632.1983.tb23265.x;
RA   Chung D.W., Rixon M.W., Que B.G., Davie E.W.;
RT   "Cloning of fibrinogen genes and their cDNA.";
RL   Ann. N. Y. Acad. Sci. 408:449-456(1983).
RN   [14]
RP   PROTEIN SEQUENCE OF 20-35.
RA   Blombaeck B., Blombaeck M., Grondahl N.J., Guthrie C., Hinton M.;
RT   "Studies on fibrinopeptides from primates.";
RL   Acta Chem. Scand. 19:1788-1789(1965).
RN   [15]
RP   DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=741445; DOI=10.1016/0049-3848(78)90142-1;
RA   Bouma H., Takagi T., Doolittle R.F.;
RT   "The arrangement of disulfide bonds in fragment D from human fibrinogen.";
RL   Thromb. Res. 13:557-562(1978).
RN   [16]
RP   CROSS-LINKING ACCEPTOR SITES.
RX   PubMed=518845; DOI=10.1021/bi00591a023;
RA   Cottrell B.A., Strong D.D., Watt K.W.K., Doolittle R.F.;
RT   "Amino acid sequence studies on the alpha chain of human fibrinogen. Exact
RT   location of cross-linking acceptor sites.";
RL   Biochemistry 18:5405-5410(1979).
RN   [17]
RP   CROSS-LINKING ACCEPTOR SITES.
RX   PubMed=632262;
RA   Fretto L.J., Ferguson E.W., Steinman H.M., McKee P.A.;
RT   "Localization of the alpha-chain cross-link acceptor sites of human
RT   fibrin.";
RL   J. Biol. Chem. 253:2184-2195(1978).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-686.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [19]
RP   DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=936108; DOI=10.1016/0049-3848(76)90245-0;
RA   Blombaeck B., Hessel B., Hogg D.;
RT   "Disulfide bridges in NH2-terminal part of human fibrinogen.";
RL   Thromb. Res. 8:639-658(1976).
RN   [20]
RP   REVIEW, ELECTRON MICROSCOPY, POLYMERIZATION, AND LIGANDS.
RX   PubMed=6383194; DOI=10.1146/annurev.bi.53.070184.001211;
RA   Doolittle R.F.;
RT   "Fibrinogen and fibrin.";
RL   Annu. Rev. Biochem. 53:195-229(1984).
RN   [21]
RP   CROSS-LINKING SITE FOR ALPHA-2-PLASMIN INHIBITOR.
RX   PubMed=2877981;
RA   Kimura S., Aoki N.;
RT   "Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor.";
RL   J. Biol. Chem. 261:15591-15595(1986).
RN   [22]
RP   PHOSPHORYLATION.
RX   PubMed=6318767; DOI=10.1016/0006-291x(83)91247-0;
RA   Itarte E., Plana M., Guasch M.D., Martos C.;
RT   "Phosphorylation of fibrinogen by casein kinase 1.";
RL   Biochem. Biophys. Res. Commun. 117:631-636(1983).
RN   [23]
RP   INTERACTION WITH STAPHYLOCOCCUS AUREUS PROTEIN FIB (MICROBIAL INFECTION).
RX   PubMed=11418620; DOI=10.1074/jbc.m104554200;
RA   Palma M., Shannon O., Quezada H.C., Berg A., Flock J.I.;
RT   "Extracellular fibrinogen-binding protein, Efb, from Staphylococcus aureus
RT   blocks platelet aggregation due to its binding to the alpha-chain.";
RL   J. Biol. Chem. 276:31691-31697(2001).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Pituitary;
RX   PubMed=16807684; DOI=10.1007/s11102-006-8916-x;
RA   Beranova-Giorgianni S., Zhao Y., Desiderio D.M., Giorgianni F.;
RT   "Phosphoproteomic analysis of the human pituitary.";
RL   Pituitary 9:109-120(2006).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-412 AND SER-609, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [26]
RP   HYDROXYLATION AT PRO-565.
RX   PubMed=19696023; DOI=10.1074/jbc.m109.041749;
RA   Ono M., Matsubara J., Honda K., Sakuma T., Hashiguchi T., Nose H.,
RA   Nakamori S., Okusaka T., Kosuge T., Sata N., Nagai H., Ioka T., Tanaka S.,
RA   Tsuchida A., Aoki T., Shimahara M., Yasunami Y., Itoi T., Moriyasu F.,
RA   Negishi A., Kuwabara H., Shoji A., Hirohashi S., Yamada T.;
RT   "Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein modification
RT   revealed by plasma proteomics.";
RL   J. Biol. Chem. 284:29041-29049(2009).
RN   [27]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-686.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [28]
RP   CLEAVAGE BY HEMENTIN AND PLASMIN.
RX   PubMed=2143188;
RA   Kirschbaum N.E., Budzynski A.Z.;
RT   "A unique proteolytic fragment of human fibrinogen containing the A alpha
RT   COOH-terminal domain of the native molecule.";
RL   J. Biol. Chem. 265:13669-13676(1990).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   GLYCOSYLATION AT THR-320 AND SER-351.
RX   PubMed=23050552; DOI=10.1021/pr3005937;
RA   Zauner G., Hoffmann M., Rapp E., Koeleman C.A., Dragan I., Deelder A.M.,
RA   Wuhrer M., Hensbergen P.J.;
RT   "Glycoproteomic analysis of human fibrinogen reveals novel regions of O-
RT   glycosylation.";
RL   J. Proteome Res. 11:5804-5814(2012).
RN   [31]
RP   INTERACTION WITH STAPHYLOCOCCUS AUREUS PROTEIN FIB (MICROBIAL INFECTION).
RX   PubMed=24348255; DOI=10.1371/journal.ppat.1003816;
RA   Ko Y.P., Kuipers A., Freitag C.M., Jongerius I., Medina E.,
RA   van Rooijen W.J., Spaan A.N., van Kessel K.P., Hoeoek M., Rooijakkers S.H.;
RT   "Phagocytosis escape by a Staphylococcus aureus protein that connects
RT   complement and coagulation proteins at the bacterial surface.";
RL   PLoS Pathog. 9:E1003816-E1003816(2013).
RN   [32]
RP   LACK OF GLYCOSYLATION.
RX   PubMed=23151259; DOI=10.1021/pr300813h;
RA   Adamczyk B., Struwe W.B., Ercan A., Nigrovic P.A., Rudd P.M.;
RT   "Characterization of fibrinogen glycosylation and its importance for
RT   serum/plasma N-glycome analysis.";
RL   J. Proteome Res. 12:444-454(2013).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-45; SER-50; SER-281; SER-291;
RP   SER-294; THR-412; SER-451; SER-501; THR-505 AND SER-609, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [34]
RP   PHOSPHORYLATION AT SER-45; SER-56; SER-364; SER-524; SER-560 AND SER-609.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-39.
RX   PubMed=1560020;
RA   Martin P.D., Robertson W., Turk D., Huber R., Bode W., Edwards B.F.P.;
RT   "The structure of residues 7-16 of the A alpha-chain of human fibrinogen
RT   bound to bovine thrombin at 2.3-A resolution.";
RL   J. Biol. Chem. 267:7911-7920(1992).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 130-216, DISULFIDE BONDS, AND
RP   SUBUNIT.
RX   PubMed=9333233; DOI=10.1038/38947;
RA   Spraggon G., Everse S.J., Doolittle R.F.;
RT   "Crystal structures of fragment D from human fibrinogen and its crosslinked
RT   counterpart from fibrin.";
RL   Nature 389:455-462(1997).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 130-216, SUBUNIT, DISULFIDE BONDS,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND COILED COIL DOMAIN.
RX   PubMed=9628725; DOI=10.1021/bi9804129;
RA   Everse S.J., Spraggon G., Veerapandian L., Riley M., Doolittle R.F.;
RT   "Crystal structure of fragment double-D from human fibrin with two
RT   different bound ligands.";
RL   Biochemistry 37:8637-8642(1998).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 666-866 IN COMPLEX WITH CALCIUM
RP   IONS, GLYCOSYLATION AT ASN-686, DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=9689040; DOI=10.1073/pnas.95.16.9099;
RA   Spraggon G., Applegate D., Everse S.J., Zhang J.Z., Veerapandian L.,
RA   Redman C., Doolittle R.F., Grieninger G.;
RT   "Crystal structure of a recombinant alphaEC domain from human fibrinogen-
RT   420.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9099-9104(1998).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 130-216, AND DISULFIDE BONDS.
RX   PubMed=10074346; DOI=10.1021/bi982626w;
RA   Everse S.J., Spraggon G., Veerapandian L., Doolittle R.F.;
RT   "Conformational changes in fragments D and double-D from human fibrin(ogen)
RT   upon binding the peptide ligand Gly-His-Arg-Pro-amide.";
RL   Biochemistry 38:2941-2946(1999).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 20-581, SUBUNIT, DISULFIDE BONDS,
RP   COILED COIL DOMAIN, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=19296670; DOI=10.1021/bi802205g;
RA   Kollman J.M., Pandi L., Sawaya M.R., Riley M., Doolittle R.F.;
RT   "Crystal structure of human fibrinogen.";
RL   Biochemistry 48:3877-3886(2009).
RN   [41]
RP   VARIANT KYOTO-2 LEU-37.
RX   PubMed=2070049;
RA   Yoshida N., Okuma M., Hirata H., Matsuda M., Yamazumi K., Asakura S.;
RT   "Fibrinogen Kyoto II, a new congenitally abnormal molecule, characterized
RT   by the replacement of A alpha proline-18 by leucine.";
RL   Blood 78:149-153(1991).
RN   [42]
RP   VARIANT LIMA SER-160.
RX   PubMed=1634621; DOI=10.1172/jci115857;
RA   Maekawa H., Yamazumi K., Muramatsu S., Kaneko M., Hirata H., Takahashi N.,
RA   Arocha-Pinango C.L., Rodriguez S., Nagy H., Perez-Requejo J.L., Matsuda M.;
RT   "Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141
RT   to serine substitution associated with extra N-glycosylation at A alpha-
RT   asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated
RT   plasminogen activation catalyzed by tissue-type plasminogen activator.";
RL   J. Clin. Invest. 90:67-76(1992).
RN   [43]
RP   GLYCOSYLATION AT ASN-453 (VARIANT ASN-453), AND VARIANT CARACAS-2 ASN-453.
RX   PubMed=1675636;
RA   Maekawa H., Yamazumi K., Muramatsu S., Kaneko M., Hirata H., Takahashi N.,
RA   de Bosch N.B., Carvajal Z., Ojeda A., Arocha-Pinango C.L., Matsuda M.;
RT   "An A alpha Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen,
RT   fibrinogen Caracas II, characterized by impaired fibrin gel formation.";
RL   J. Biol. Chem. 266:11575-11581(1991).
RN   [44]
RP   INVOLVEMENT IN DYSFIBRIN, AND VARIANT DYSFIBRIN CYS-573.
RX   PubMed=8473507; DOI=10.1172/jci116371;
RA   Koopman J., Haverkate F., Grimbergen J., Lord S.T., Mosesson M.W.,
RA   Diorio J.P., Siebenlist K.S., Legrand C., Soria J., Soria C., Caen J.P.;
RT   "Molecular basis for fibrinogen Dusart (A alpha 554 Arg-->Cys) and its
RT   association with abnormal fibrin polymerization and thrombophilia.";
RL   J. Clin. Invest. 91:1637-1643(1993).
RN   [45]
RP   VARIANT AMYL8 LEU-573.
RX   PubMed=8097946; DOI=10.1038/ng0393-252;
RA   Benson M.D., Liepnieks J., Uemichi T., Wheeler G., Correa R.;
RT   "Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-
RT   chain.";
RL   Nat. Genet. 3:252-255(1993).
RN   [46]
RP   VARIANT OSAKA IV HIS-35.
RX   PubMed=8461606; DOI=10.1007/bf00308999;
RA   Yamazumi K., Terukina S., Matsuda M., Kanbayashi J., Sakon M.,
RA   Tsujinaka T.;
RT   "Fibrinogen Osaka IV: a congenital dysfibrinogenemia found in a patient
RT   originally reported in relation to surgery, now defined to have an A alpha
RT   arginine-16 to histidine substitution.";
RL   Surg. Today 23:45-50(1993).
RN   [47]
RP   VARIANT CANTERBURY ASP-39.
RX   PubMed=8675656; DOI=10.1172/jci118356;
RA   Brennan S.O., Hammonds B., George P.M.;
RT   "Aberrant hepatic processing causes removal of activation peptide and
RT   primary polymerisation site from fibrinogen Canterbury (A-alpha 20 Val-to-
RT   Asp).";
RL   J. Clin. Invest. 96:2854-2858(1995).
RN   [48]
RP   VARIANTS ALA-331 AND GLU-446.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [49]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [50]
RP   INVOLVEMENT IN DYSFIBRIN, AND VARIANT DYSFIBRIN CYS-35.
RX   PubMed=16846481; DOI=10.1111/j.1365-2141.2006.06129.x;
RA   Flood V.H., Al-Mondhiry H.A., Farrell D.H.;
RT   "The fibrinogen Aalpha R16C mutation results in fibrinolytic resistance.";
RL   Br. J. Haematol. 134:220-226(2006).
RN   [51]
RP   INVOLVEMENT IN CAFBN; VARIANTS CAFBN ARG-55; PRO-129 AND TRP-184, AND
RP   CHARACTERIZATION OF VARIANTS CAFBN ARG-55; PRO-129 AND TRP-184.
RX   PubMed=25427968; DOI=10.1160/th14-07-0629;
RA   Asselta R., Plate M., Robusto M., Borhany M., Guella I., Solda G.,
RA   Afrasiabi A., Menegatti M., Shamsi T., Peyvandi F., Duga S.;
RT   "Clinical and molecular characterisation of 21 patients affected by
RT   quantitative fibrinogen deficiency.";
RL   Thromb. Haemost. 113:567-576(2015).
CC   -!- FUNCTION: Cleaved by the protease thrombin to yield monomers which,
CC       together with fibrinogen beta (FGB) and fibrinogen gamma (FGG),
CC       polymerize to form an insoluble fibrin matrix. Fibrin has a major
CC       function in hemostasis as one of the primary components of blood clots.
CC       In addition, functions during the early stages of wound repair to
CC       stabilize the lesion and guide cell migration during re-
CC       epithelialization. Was originally thought to be essential for platelet
CC       aggregation, based on in vitro studies using anticoagulated blood.
CC       However, subsequent studies have shown that it is not absolutely
CC       required for thrombus formation in vivo. Enhances expression of SELP in
CC       activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen
CC       is essential for successful pregnancy. Fibrin deposition is also
CC       associated with infection, where it protects against IFNG-mediated
CC       hemorrhage. May also facilitate the immune response via both innate and
CC       T-cell mediated pathways. {ECO:0000250|UniProtKB:E9PV24}.
CC   -!- SUBUNIT: Heterohexamer; disulfide linked. Contains 2 sets of 3 non-
CC       identical chains (alpha, beta and gamma). The 2 heterotrimers are in
CC       head to head conformation with the N-termini in a small central domain.
CC       {ECO:0000269|PubMed:518846, ECO:0000269|PubMed:741445,
CC       ECO:0000269|PubMed:9333233, ECO:0000269|PubMed:936108,
CC       ECO:0000269|PubMed:9628725, ECO:0000269|PubMed:9689040}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Staphylococcus aureus
CC       protein Fib; this interaction inhibits fibrinogen-dependent platelet
CC       aggregation and protects the bacteria form phagocytosis.
CC       {ECO:0000269|PubMed:11418620, ECO:0000269|PubMed:24348255}.
CC   -!- INTERACTION:
CC       P02671; Q8IXL6: FAM20C; NbExp=2; IntAct=EBI-348571, EBI-7147442;
CC       P02671-2; O00471: EXOC5; NbExp=3; IntAct=EBI-9640259, EBI-949824;
CC       P02671-2; P13473-2: LAMP2; NbExp=3; IntAct=EBI-9640259, EBI-21591415;
CC       P02671-2; Q9Y3L3: SH3BP1; NbExp=3; IntAct=EBI-9640259, EBI-346869;
CC       P02671-2; Q9Y371: SH3GLB1; NbExp=3; IntAct=EBI-9640259, EBI-2623095;
CC       P02671-2; P00441: SOD1; NbExp=3; IntAct=EBI-9640259, EBI-990792;
CC       P02671-2; P61266: STX1B; NbExp=3; IntAct=EBI-9640259, EBI-9071709;
CC       P02671-2; P32856-2: STX2; NbExp=3; IntAct=EBI-9640259, EBI-11956649;
CC       P02671-2; Q9UBB9: TFIP11; NbExp=3; IntAct=EBI-9640259, EBI-1105213;
CC       P02671-2; Q9BTV4: TMEM43; NbExp=3; IntAct=EBI-9640259, EBI-721293;
CC       P02671-2; P09493-10: TPM1; NbExp=3; IntAct=EBI-9640259, EBI-12123928;
CC       P02671-2; P06753: TPM3; NbExp=3; IntAct=EBI-9640259, EBI-355607;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:19296670,
CC       ECO:0000269|PubMed:9628725}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Alpha-E;
CC         IsoId=P02671-1; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha;
CC         IsoId=P02671-2; Sequence=VSP_001531, VSP_001532;
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma (at protein level).
CC       {ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9628725}.
CC   -!- DOMAIN: A long coiled coil structure formed by 3 polypeptide chains
CC       connects the central nodule to the C-terminal domains (distal nodules).
CC       The long C-terminal ends of the alpha chains fold back, contributing a
CC       fourth strand to the coiled coil structure.
CC       {ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9628725, ECO:0000305}.
CC   -!- PTM: The alpha chain is normally not N-glycosylated (PubMed:23151259),
CC       even though glycosylation at Asn-686 was observed when a fragment of
CC       the protein was expressed in insect cells (PubMed:9689040). It is well
CC       known that heterologous expression of isolated domains can lead to
CC       adventitious protein modifications. Besides, glycosylation at Asn-686
CC       is supported by large-scale glycoproteomics studies (PubMed:16335952
CC       and PubMed:19159218), but the evidence is still quite tenuous. Most
CC       likely, Asn-686 is not glycosylated in the healthy human body, or only
CC       with low efficiency. {ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23151259,
CC       ECO:0000269|PubMed:9689040, ECO:0000305}.
CC   -!- PTM: O-glycosylated. {ECO:0000269|PubMed:23050552}.
CC   -!- PTM: Forms F13A-mediated cross-links between a glutamine and the
CC       epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen
CC       heteropolymers.
CC   -!- PTM: About one-third of the alpha chains in the molecules in blood were
CC       found to be phosphorylated.
CC   -!- PTM: Conversion of fibrinogen to fibrin is triggered by thrombin, which
CC       cleaves fibrinopeptides A and B from alpha and beta chains, and thus
CC       exposes the N-terminal polymerization sites responsible for the
CC       formation of the soft clot. The soft clot is converted into the hard
CC       clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine
CC       cross-linking between gamma chains (stronger) and between alpha chains
CC       (weaker) of different monomers. {ECO:0000269|PubMed:2143188}.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- DISEASE: Congenital afibrinogenemia (CAFBN) [MIM:202400]: Rare
CC       autosomal recessive disorder is characterized by bleeding that varies
CC       from mild to severe and by complete absence or extremely low levels of
CC       plasma and platelet fibrinogen. {ECO:0000269|PubMed:25427968}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry. The majority of cases of afibrinogenemia are due to truncating
CC       mutations. Variations in position Arg-35 (the site of cleavage of
CC       fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.
CC   -!- DISEASE: Amyloidosis 8 (AMYL8) [MIM:105200]: A form of hereditary
CC       generalized amyloidosis. Clinical features include extensive visceral
CC       amyloid deposits, renal amyloidosis resulting in nephrotic syndrome,
CC       arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin
CC       rash. There is no involvement of the nervous system.
CC       {ECO:0000269|PubMed:8097946}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Dysfibrinogenemia, congenital (DYSFIBRIN) [MIM:616004]: A
CC       disorder characterized by qualitative abnormalities (dysfibrinogenemia)
CC       of the circulating fibrinogen. Affected individuals are frequently
CC       asymptomatic, but some patients have bleeding diathesis, thromboembolic
CC       complications, or both. In some cases, dysfibrinogenemia is associated
CC       with low circulating fibrinogen levels (hypodysfibrinogenemia).
CC       {ECO:0000269|PubMed:16846481, ECO:0000269|PubMed:8473507}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=FGA";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Fibrinogen entry;
CC       URL="https://en.wikipedia.org/wiki/Fibrinogen";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/fga/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M64982; AAA17056.1; -; Genomic_DNA.
DR   EMBL; M64982; AAA17055.1; -; Genomic_DNA.
DR   EMBL; M58569; AAC97142.1; -; Transcribed_RNA.
DR   EMBL; M58569; AAC97143.1; -; Transcribed_RNA.
DR   EMBL; AF361104; AAK31372.1; -; Genomic_DNA.
DR   EMBL; AF361104; AAK31373.1; -; Genomic_DNA.
DR   EMBL; AK290559; BAF83248.1; -; mRNA.
DR   EMBL; CH471056; EAX04925.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04926.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04927.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04928.1; -; Genomic_DNA.
DR   EMBL; BC098280; AAH98280.1; -; mRNA.
DR   EMBL; BC099706; AAH99706.1; -; mRNA.
DR   EMBL; BC099720; AAH99720.1; -; mRNA.
DR   EMBL; BC101935; AAI01936.1; -; mRNA.
DR   EMBL; J00128; AAA52427.1; -; mRNA.
DR   EMBL; J00127; AAA52426.1; -; mRNA.
DR   EMBL; K02272; AAA52428.1; -; mRNA.
DR   EMBL; M26878; AAA52444.1; -; mRNA.
DR   CCDS; CCDS3787.1; -. [P02671-1]
DR   CCDS; CCDS47152.1; -. [P02671-2]
DR   PIR; A93956; FGHUA.
DR   PIR; D44234; D44234.
DR   RefSeq; NP_000499.1; NM_000508.4. [P02671-1]
DR   RefSeq; NP_068657.1; NM_021871.3. [P02671-2]
DR   PDB; 1BBR; X-ray; 2.30 A; F/G/I=26-35.
DR   PDB; 1DM4; X-ray; 2.50 A; C=26-35.
DR   PDB; 1FPH; X-ray; 2.50 A; F=26-35.
DR   PDB; 1FZA; X-ray; 2.90 A; A/D=130-216.
DR   PDB; 1FZB; X-ray; 2.90 A; A/D=130-216.
DR   PDB; 1FZC; X-ray; 2.30 A; A/D=130-216.
DR   PDB; 1FZD; X-ray; 2.10 A; A/B/C/D/E/F/G/H=666-866.
DR   PDB; 1FZE; X-ray; 3.00 A; A/D=130-216.
DR   PDB; 1FZF; X-ray; 2.70 A; A/D=130-216.
DR   PDB; 1FZG; X-ray; 2.50 A; A/D=130-216.
DR   PDB; 1LT9; X-ray; 2.80 A; A/D=145-210.
DR   PDB; 1LTJ; X-ray; 2.80 A; A/D=145-210.
DR   PDB; 1N86; X-ray; 3.20 A; A/D=130-216.
DR   PDB; 1N8E; X-ray; 4.50 A; A/D=130-218.
DR   PDB; 1RE3; X-ray; 2.45 A; A/D=145-210.
DR   PDB; 1RE4; X-ray; 2.70 A; A/D=145-210.
DR   PDB; 1RF0; X-ray; 2.81 A; A/D=145-210.
DR   PDB; 1RF1; X-ray; 2.53 A; A/D=145-210.
DR   PDB; 1YCP; X-ray; 2.50 A; F/N=20-42.
DR   PDB; 2A45; X-ray; 3.65 A; G/J=36-92.
DR   PDB; 2FFD; X-ray; 2.89 A; A/D=145-210.
DR   PDB; 2H43; X-ray; 2.70 A; A/D=130-216.
DR   PDB; 2HLO; X-ray; 2.60 A; A/D=130-216.
DR   PDB; 2HOD; X-ray; 2.90 A; A/D/G/J=130-216.
DR   PDB; 2HPC; X-ray; 2.90 A; A/D/G/J=130-216.
DR   PDB; 2OYH; X-ray; 2.40 A; A/D=145-210.
DR   PDB; 2OYI; X-ray; 2.70 A; A/D=145-210.
DR   PDB; 2Q9I; X-ray; 2.80 A; A/D=130-216.
DR   PDB; 2XNX; X-ray; 3.30 A; A/D/G/J=130-216.
DR   PDB; 2XNY; X-ray; 7.50 A; A/D=130-216.
DR   PDB; 2Z4E; X-ray; 2.70 A; A/D=130-216.
DR   PDB; 3AT0; X-ray; 2.50 A; B=332-347.
DR   PDB; 3BVH; X-ray; 2.60 A; A/D=148-209.
DR   PDB; 3E1I; X-ray; 2.30 A; A/D=130-216.
DR   PDB; 3GHG; X-ray; 2.90 A; A/D/G/J=20-581.
DR   PDB; 3H32; X-ray; 3.60 A; A/D=20-216.
DR   PDB; 3HUS; X-ray; 3.04 A; A/D=145-210.
DR   PDB; 4F27; X-ray; 1.92 A; Q=336-347.
DR   PDB; 5CFA; X-ray; 1.45 A; C/D=580-594.
DR   PDBsum; 1BBR; -.
DR   PDBsum; 1DM4; -.
DR   PDBsum; 1FPH; -.
DR   PDBsum; 1FZA; -.
DR   PDBsum; 1FZB; -.
DR   PDBsum; 1FZC; -.
DR   PDBsum; 1FZD; -.
DR   PDBsum; 1FZE; -.
DR   PDBsum; 1FZF; -.
DR   PDBsum; 1FZG; -.
DR   PDBsum; 1LT9; -.
DR   PDBsum; 1LTJ; -.
DR   PDBsum; 1N86; -.
DR   PDBsum; 1N8E; -.
DR   PDBsum; 1RE3; -.
DR   PDBsum; 1RE4; -.
DR   PDBsum; 1RF0; -.
DR   PDBsum; 1RF1; -.
DR   PDBsum; 1YCP; -.
DR   PDBsum; 2A45; -.
DR   PDBsum; 2FFD; -.
DR   PDBsum; 2H43; -.
DR   PDBsum; 2HLO; -.
DR   PDBsum; 2HOD; -.
DR   PDBsum; 2HPC; -.
DR   PDBsum; 2OYH; -.
DR   PDBsum; 2OYI; -.
DR   PDBsum; 2Q9I; -.
DR   PDBsum; 2XNX; -.
DR   PDBsum; 2XNY; -.
DR   PDBsum; 2Z4E; -.
DR   PDBsum; 3AT0; -.
DR   PDBsum; 3BVH; -.
DR   PDBsum; 3E1I; -.
DR   PDBsum; 3GHG; -.
DR   PDBsum; 3H32; -.
DR   PDBsum; 3HUS; -.
DR   PDBsum; 4F27; -.
DR   PDBsum; 5CFA; -.
DR   SMR; P02671; -.
DR   BioGRID; 108534; 49.
DR   ComplexPortal; CPX-1922; Fibrinogen complex.
DR   ComplexPortal; CPX-6225; Fibrin complex.
DR   CORUM; P02671; -.
DR   DIP; DIP-29643N; -.
DR   IntAct; P02671; 41.
DR   MINT; P02671; -.
DR   STRING; 9606.ENSP00000306361; -.
DR   ChEMBL; CHEMBL2364709; -.
DR   DrugBank; DB04919; Alfimeprase.
DR   DrugBank; DB00009; Alteplase.
DR   DrugBank; DB05099; Ancrod.
DR   DrugBank; DB00029; Anistreplase.
DR   DrugBank; DB13151; Anti-inhibitor coagulant complex.
DR   DrugBank; DB05675; EP-2104R.
DR   DrugBank; DB11571; Human thrombin.
DR   DrugBank; DB06245; Lanoteplase.
DR   DrugBank; DB11311; Prothrombin.
DR   DrugBank; DB00015; Reteplase.
DR   DrugBank; DB00364; Sucralfate.
DR   DrugBank; DB00031; Tenecteplase.
DR   DrugBank; DB11300; Thrombin.
DR   DrugBank; DB11572; Thrombin alfa.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugBank; DB14548; Zinc sulfate, unspecified form.
DR   CarbonylDB; P02671; -.
DR   GlyConnect; 1238; 3 N-Linked glycans (1 site).
DR   GlyConnect; 157; 4 N-Linked glycans.
DR   GlyGen; P02671; 23 sites, 4 O-linked glycans (21 sites).
DR   iPTMnet; P02671; -.
DR   PhosphoSitePlus; P02671; -.
DR   SwissPalm; P02671; -.
DR   BioMuta; FGA; -.
DR   DMDM; 1706799; -.
DR   OGP; P02671; -.
DR   SWISS-2DPAGE; P02671; -.
DR   CPTAC; non-CPTAC-1117; -.
DR   CPTAC; non-CPTAC-1118; -.
DR   jPOST; P02671; -.
DR   MassIVE; P02671; -.
DR   MaxQB; P02671; -.
DR   PaxDb; P02671; -.
DR   PeptideAtlas; P02671; -.
DR   PRIDE; P02671; -.
DR   ProteomicsDB; 51542; -. [P02671-1]
DR   ProteomicsDB; 51543; -. [P02671-2]
DR   Antibodypedia; 3395; 1021 antibodies.
DR   DNASU; 2243; -.
DR   Ensembl; ENST00000403106; ENSP00000385981; ENSG00000171560. [P02671-2]
DR   Ensembl; ENST00000651975; ENSP00000498441; ENSG00000171560. [P02671-1]
DR   GeneID; 2243; -.
DR   KEGG; hsa:2243; -.
DR   UCSC; uc003iod.2; human. [P02671-1]
DR   CTD; 2243; -.
DR   DisGeNET; 2243; -.
DR   GeneCards; FGA; -.
DR   HGNC; HGNC:3661; FGA.
DR   HPA; ENSG00000171560; Tissue enriched (liver).
DR   MalaCards; FGA; -.
DR   MIM; 105200; phenotype.
DR   MIM; 134820; gene+phenotype.
DR   MIM; 202400; phenotype.
DR   MIM; 616004; phenotype.
DR   neXtProt; NX_P02671; -.
DR   OpenTargets; ENSG00000171560; -.
DR   Orphanet; 93562; AFib amyloidosis.
DR   Orphanet; 98880; Familial afibrinogenemia.
DR   Orphanet; 98881; Familial dysfibrinogenemia.
DR   Orphanet; 248408; Familial hypodysfibrinogenemia.
DR   Orphanet; 101041; Familial hypofibrinogenemia.
DR   PharmGKB; PA429; -.
DR   VEuPathDB; HostDB:ENSG00000171560.14; -.
DR   eggNOG; KOG2579; Eukaryota.
DR   GeneTree; ENSGT00940000157467; -.
DR   HOGENOM; CLU_013807_0_0_1; -.
DR   InParanoid; P02671; -.
DR   OMA; WVSFRGA; -.
DR   OrthoDB; 363208at2759; -.
DR   PhylomeDB; P02671; -.
DR   TreeFam; TF351984; -.
DR   PathwayCommons; P02671; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-140875; Common Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-354192; Integrin signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5686938; Regulation of TLR by endogenous ligand.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   SIGNOR; P02671; -.
DR   BioGRID-ORCS; 2243; 6 hits in 988 CRISPR screens.
DR   ChiTaRS; FGA; human.
DR   EvolutionaryTrace; P02671; -.
DR   GeneWiki; Fibrinogen_alpha_chain; -.
DR   GenomeRNAi; 2243; -.
DR   Pharos; P02671; Tbio.
DR   PRO; PR:P02671; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P02671; protein.
DR   Bgee; ENSG00000171560; Expressed in liver and 129 other tissues.
DR   ExpressionAtlas; P02671; baseline and differential.
DR   Genevisible; P02671; HS.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB.
DR   GO; GO:0005577; C:fibrinogen complex; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031091; C:platelet alpha granule; IDA:BHF-UCL.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0005201; F:extracellular matrix structural constituent; HDA:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0005102; F:signaling receptor binding; IEA:InterPro.
DR   GO; GO:0005198; F:structural molecule activity; IDA:BHF-UCL.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:1990000; P:amyloid fibril formation; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0072377; P:blood coagulation, common pathway; IMP:BHF-UCL.
DR   GO; GO:0072378; P:blood coagulation, fibrin clot formation; IDA:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0034622; P:cellular protein-containing complex assembly; IDA:BHF-UCL.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0042730; P:fibrinolysis; IDA:UniProtKB.
DR   GO; GO:0043152; P:induction of bacterial agglutination; IDA:CACAO.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:2000261; P:negative regulation of blood coagulation, common pathway; TAS:BHF-UCL.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0031639; P:plasminogen activation; IDA:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; IDA:BHF-UCL.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IDA:BHF-UCL.
DR   GO; GO:0034116; P:positive regulation of heterotypic cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0090277; P:positive regulation of peptide hormone secretion; IDA:BHF-UCL.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; NAS:BHF-UCL.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IDA:BHF-UCL.
DR   GO; GO:0043687; P:post-translational protein modification; TAS:Reactome.
DR   GO; GO:0051258; P:protein polymerization; IDA:BHF-UCL.
DR   GO; GO:0065003; P:protein-containing complex assembly; IMP:UniProtKB.
DR   GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   CDD; cd00087; FReD; 1.
DR   DisProt; DP02130; -.
DR   InterPro; IPR036056; Fibrinogen-like_C.
DR   InterPro; IPR002181; Fibrinogen_a/b/g_C_dom.
DR   InterPro; IPR012290; Fibrinogen_a/b/g_coil_dom.
DR   InterPro; IPR021996; Fibrinogen_aC.
DR   InterPro; IPR037579; Fibrinogen_alpha.
DR   InterPro; IPR020837; Fibrinogen_CS.
DR   PANTHER; PTHR47221; PTHR47221; 1.
DR   Pfam; PF08702; Fib_alpha; 1.
DR   Pfam; PF12160; Fibrinogen_aC; 1.
DR   Pfam; PF00147; Fibrinogen_C; 1.
DR   SMART; SM00186; FBG; 1.
DR   SMART; SM01212; Fib_alpha; 1.
DR   SUPFAM; SSF56496; SSF56496; 1.
DR   PROSITE; PS00514; FIBRINOGEN_C_1; 1.
DR   PROSITE; PS51406; FIBRINOGEN_C_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; Amyloid;
KW   Amyloidosis; Blood coagulation; Calcium; Coiled coil;
KW   Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein;
KW   Hemostasis; Hydroxylation; Immunity; Innate immunity; Isopeptide bond;
KW   Metal-binding; Phosphoprotein; Reference proteome; Secreted; Signal.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000269|PubMed:518846, ECO:0000269|Ref.10,
FT                   ECO:0000269|Ref.14"
FT   PEPTIDE         20..35
FT                   /note="Fibrinopeptide A"
FT                   /id="PRO_0000009021"
FT   CHAIN           36..866
FT                   /note="Fibrinogen alpha chain"
FT                   /id="PRO_0000009022"
FT   DOMAIN          623..864
FT                   /note="Fibrinogen C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00739"
FT   REGION          36..38
FT                   /note="Alpha-chain polymerization, binding distal domain of
FT                   another fibrin gamma chain"
FT   COILED          68..631
FT                   /evidence="ECO:0000305|PubMed:19296670"
FT   METAL           791
FT                   /note="Calcium"
FT                   /evidence="ECO:0000269|PubMed:9689040,
FT                   ECO:0007744|PDB:1FZD"
FT   METAL           793
FT                   /note="Calcium"
FT                   /evidence="ECO:0000269|PubMed:9689040,
FT                   ECO:0007744|PDB:1FZD"
FT   METAL           795
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000269|PubMed:9689040,
FT                   ECO:0007744|PDB:1FZD"
FT   METAL           797
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000269|PubMed:9689040,
FT                   ECO:0007744|PDB:1FZD"
FT   SITE            35..36
FT                   /note="Cleavage; by thrombin; to release fibrinopeptide A"
FT   SITE            100..101
FT                   /note="Cleavage; by plasmin; to break down fibrin clots"
FT   SITE            121..122
FT                   /note="Cleavage; by hementin; to prevent blood coagulation"
FT   SITE            123..124
FT                   /note="Cleavage; by plasmin; to break down fibrin clots"
FT   MOD_RES         22
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16807684"
FT   MOD_RES         45
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         50
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         56
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039"
FT   MOD_RES         281
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         291
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         364
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039"
FT   MOD_RES         412
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         451
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         501
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         505
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         524
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039"
FT   MOD_RES         560
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039"
FT   MOD_RES         565
FT                   /note="4-hydroxyproline; by P4HA1"
FT                   /evidence="ECO:0000269|PubMed:19696023"
FT   MOD_RES         609
FT                   /note="Phosphoserine; by FAM20C"
FT                   /evidence="ECO:0000269|PubMed:26091039,
FT                   ECO:0007744|PubMed:18088087, ECO:0007744|PubMed:24275569"
FT   CARBOHYD        320
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000269|PubMed:23050552"
FT   CARBOHYD        351
FT                   /note="O-linked (GalNAc...) serine"
FT                   /evidence="ECO:0000269|PubMed:23050552"
FT   CARBOHYD        453
FT                   /note="N-linked (GlcNAc...) asparagine; in variant Caracas-
FT                   2"
FT                   /evidence="ECO:0000269|PubMed:1675636"
FT   CARBOHYD        686
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:9689040"
FT   DISULFID        47
FT                   /note="Interchain"
FT                   /evidence="ECO:0000269|PubMed:19296670"
FT   DISULFID        55
FT                   /note="Interchain (with C-95 in beta chain)"
FT                   /evidence="ECO:0000269|PubMed:19296670"
FT   DISULFID        64
FT                   /note="Interchain (with C-49 in gamma chain)"
FT                   /evidence="ECO:0000269|PubMed:19296670"
FT   DISULFID        68
FT                   /note="Interchain (with C-106 in beta chain)"
FT                   /evidence="ECO:0000269|PubMed:19296670"
FT   DISULFID        180
FT                   /note="Interchain (with C-165 in gamma chain)"
FT                   /evidence="ECO:0000269|PubMed:19296670,
FT                   ECO:0000269|PubMed:741445, ECO:0000269|PubMed:9333233,
FT                   ECO:0000269|PubMed:9628725"
FT   DISULFID        184
FT                   /note="Interchain (with C-223 in beta chain)"
FT                   /evidence="ECO:0000269|PubMed:19296670,
FT                   ECO:0000269|PubMed:741445, ECO:0000269|PubMed:9333233,
FT                   ECO:0000269|PubMed:9628725"
FT   DISULFID        461..491
FT                   /evidence="ECO:0000250|UniProtKB:P02672"
FT   DISULFID        799..812
FT                   /evidence="ECO:0000269|PubMed:9689040,
FT                   ECO:0007744|PDB:1FZD"
FT   CROSSLNK        322
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-41 in alpha-2-antiplasmin)"
FT   CROSSLNK        347
FT                   /note="Isoglutamyl lysine isopeptide (Gln-Lys) (interchain
FT                   with K-?)"
FT   CROSSLNK        385
FT                   /note="Isoglutamyl lysine isopeptide (Gln-Lys) (interchain
FT                   with K-?)"
FT   CROSSLNK        527
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000255"
FT   CROSSLNK        558
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000255"
FT   CROSSLNK        575
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000255"
FT   CROSSLNK        581
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000255"
FT   CROSSLNK        599
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         631..644
FT                   /note="DCDDVLQTHPSGTQ -> GIHTSPLGKPSLSP (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:6575389"
FT                   /id="VSP_001531"
FT   VAR_SEQ         645..866
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:6575389"
FT                   /id="VSP_001532"
FT   VARIANT         6
FT                   /note="I -> V (in dbSNP:rs2070025)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_011609"
FT   VARIANT         26
FT                   /note="D -> N (in Lille-1; dbSNP:rs121909604)"
FT                   /id="VAR_002390"
FT   VARIANT         31
FT                   /note="G -> V (in Rouen-1; dbSNP:rs121909605)"
FT                   /id="VAR_002391"
FT   VARIANT         35
FT                   /note="R -> C (in DYSFIBRIN; fibrinogen Metz 1/Hershey III;
FT                   dbSNP:rs121909606)"
FT                   /evidence="ECO:0000269|PubMed:16846481"
FT                   /id="VAR_002392"
FT   VARIANT         35
FT                   /note="R -> H (in dbSNP:rs121909607)"
FT                   /evidence="ECO:0000269|PubMed:8461606"
FT                   /id="VAR_002393"
FT   VARIANT         37
FT                   /note="P -> L (in Kyoto-2; dbSNP:rs121909609)"
FT                   /evidence="ECO:0000269|PubMed:2070049"
FT                   /id="VAR_002394"
FT   VARIANT         38
FT                   /note="R -> G (in Aarhus-1; dbSNP:rs121909608)"
FT                   /id="VAR_002397"
FT   VARIANT         38
FT                   /note="R -> N (in Munich-1; requires 2 nucleotide
FT                   substitutions)"
FT                   /id="VAR_002395"
FT   VARIANT         38
FT                   /note="R -> S (in Detroit-1; dbSNP:rs1403508334)"
FT                   /id="VAR_002396"
FT   VARIANT         39
FT                   /note="V -> D (in Canterbury; dbSNP:rs121909614)"
FT                   /evidence="ECO:0000269|PubMed:8675656"
FT                   /id="VAR_010730"
FT   VARIANT         55
FT                   /note="C -> R (in CAFBN; hypofibrinogenemia; heterozygous;
FT                   decreased fibrinogen complex assembly; no effect on
FT                   fibrinogen complex secretion)"
FT                   /evidence="ECO:0000269|PubMed:25427968"
FT                   /id="VAR_072721"
FT   VARIANT         66
FT                   /note="S -> T"
FT                   /id="VAR_002398"
FT   VARIANT         129
FT                   /note="R -> P (in CAFBN; hypofibrinogenemia; heterozygous;
FT                   no effect on fibrinogen complex assembly; no effect on
FT                   fibrinogen complex secretion)"
FT                   /evidence="ECO:0000269|PubMed:25427968"
FT                   /id="VAR_072722"
FT   VARIANT         160
FT                   /note="R -> S (in Lima)"
FT                   /evidence="ECO:0000269|PubMed:1634621"
FT                   /id="VAR_002399"
FT   VARIANT         184
FT                   /note="C -> W (in CAFBN; hypofibrinogenemia; heterozygous;
FT                   impaired fibrinogen complex assembly)"
FT                   /evidence="ECO:0000269|PubMed:25427968"
FT                   /id="VAR_072723"
FT   VARIANT         331
FT                   /note="T -> A (in dbSNP:rs6050)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|Ref.3"
FT                   /id="VAR_011610"
FT   VARIANT         446
FT                   /note="K -> E (in dbSNP:rs6052)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_014168"
FT   VARIANT         453
FT                   /note="S -> N (in Caracas-2; dbSNP:rs121909610)"
FT                   /evidence="ECO:0000269|PubMed:1675636"
FT                   /id="VAR_002400"
FT   VARIANT         456
FT                   /note="T -> A (in dbSNP:rs2070031)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_011611"
FT   VARIANT         545
FT                   /note="E -> V (in AMYL8; dbSNP:rs121909612)"
FT                   /id="VAR_010731"
FT   VARIANT         573
FT                   /note="R -> C (in DYSFIBRIN; fibrinogen Dusart/Paris-5;
FT                   dbSNP:rs121909613)"
FT                   /evidence="ECO:0000269|PubMed:8473507"
FT                   /id="VAR_002401"
FT   VARIANT         573
FT                   /note="R -> L (in AMYL8; dbSNP:rs78506343)"
FT                   /evidence="ECO:0000269|PubMed:8097946"
FT                   /id="VAR_010732"
FT   CONFLICT        177
FT                   /note="I -> V (in Ref. 4; BAF83248)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        215..216
FT                   /note="SR -> RS (in Ref. 10; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        299
FT                   /note="S -> G (in Ref. 10; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        304
FT                   /note="S -> G (in Ref. 10; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        317..318
FT                   /note="GT -> SG (in Ref. 11; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   TURN            27..31
FT                   /evidence="ECO:0007744|PDB:1BBR"
FT   STRAND          57..60
FT                   /evidence="ECO:0007744|PDB:3GHG"
FT   STRAND          63..65
FT                   /evidence="ECO:0007744|PDB:3GHG"
FT   HELIX           67..92
FT                   /evidence="ECO:0007744|PDB:3GHG"
FT   HELIX           94..111
FT                   /evidence="ECO:0007744|PDB:3GHG"
FT   HELIX           116..129
FT                   /evidence="ECO:0007744|PDB:3GHG"
FT   TURN            133..135
FT                   /evidence="ECO:0007744|PDB:1FZA"
FT   TURN            139..141
FT                   /evidence="ECO:0007744|PDB:1FZC"
FT   HELIX           142..178
FT                   /evidence="ECO:0007744|PDB:1FZC"
FT   TURN            179..183
FT                   /evidence="ECO:0007744|PDB:1FZC"
FT   STRAND          184..186
FT                   /evidence="ECO:0007744|PDB:1RE3"
FT   HELIX           195..209
FT                   /evidence="ECO:0007744|PDB:1FZC"
FT   TURN            226..228
FT                   /evidence="ECO:0007744|PDB:3GHG"
FT   STRAND          337..343
FT                   /evidence="ECO:0007744|PDB:4F27"
FT   STRAND          582..587
FT                   /evidence="ECO:0007744|PDB:5CFA"
FT   STRAND          673..681
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   HELIX           689..694
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   HELIX           711..718
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   STRAND          723..729
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   STRAND          735..744
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   TURN            747..751
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   STRAND          753..762
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   TURN            765..768
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   TURN            771..773
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   HELIX           775..778
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   STRAND          793..797
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   HELIX           799..803
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   STRAND          810..812
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   STRAND          814..816
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   STRAND          823..826
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   HELIX           829..831
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   STRAND          840..843
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   HELIX           844..847
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   STRAND          854..861
FT                   /evidence="ECO:0007744|PDB:1FZD"
FT   CONFLICT        P02671-2:640..644
FT                   /note="PSLSP -> LPCPPRLS (in Ref. 3; AAK31372)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   866 AA;  94973 MW;  EA73A81204D8AEC4 CRC64;
     MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS DWPFCSDEDW
     NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK DSHSLTTNIM EILRGDFSSA
     NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC
     RGSCSRALAR EVDLKDYEDQ QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ
     LQKVPPEWKA LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS
     GPGSTGNRNP GSSGTGGTAT WKPGSSGPGS TGSWNSGSSG TGSTGNQNPG SPRPGSTGTW
     NPGSSERGSA GHWTSESSVS GSTGQWHSES GSFRPDSPGS GNARPNNPDW GTFEEVSGNV
     SPGTRREYHT EKLVTSKGDK ELRTGKEKVT SGSTTTTRRS CSKTVTKTVI GPDGHKEVTK
     EVVTSEDGSD CPEAMDLGTL SGIGTLDGFR HRHPDEAAFF DTASTGKTFP GFFSPMLGEF
     VSETESRGSE SGIFTNTKES SSHHPGIAEF PSRGKSSSYS KQFTSSTSYN RGDSTFESKS
     YKMADEAGSE ADHEGTHSTK RGHAKSRPVR DCDDVLQTHP SGTQSGIFNI KLPGSSKIFS
     VYCDQETSLG GWLLIQQRMD GSLNFNRTWQ DYKRGFGSLN DEGEGEFWLG NDYLHLLTQR
     GSVLRVELED WAGNEAYAEY HFRVGSEAEG YALQVSSYEG TAGDALIEGS VEEGAEYTSH
     NNMQFSTFDR DADQWEENCA EVYGGGWWYN NCQAANLNGI YYPGGSYDPR NNSPYEIENG
     VVWVSFRGAD YSLRAVRMKI RPLVTQ
//
